Export 10 results:
Author [ Title
Filters: Author is Gordon, Ingelise J [Clear All Filters]
“Chimpanzee Adenovirus Vector Ebola Vaccine.”, N Engl J Med, vol. 376, no. 10, pp. 928-938, 2017.
, “DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.”, Lancet Infect Dis, vol. 11, no. 12, pp. 916-24, 2011.
, , “Phase 1 study of pandemic H1 DNA vaccine in healthy adults.”, PLoS One, vol. 10, no. 4, p. e0123969, 2015.
, “Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).”, PLoS One, vol. 9, no. 3, p. e91366, 2014.
, “Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.”, Science, vol. 341, no. 6152, pp. 1359-65, 2013.
, “Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.”, Vaccine, vol. 25, no. 8, pp. 1513-25, 2007.
, “A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.”, Vaccine, vol. 26, no. 50, pp. 6338-43, 2008.
, “Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.”, J Infect Dis, vol. 207, no. 12, pp. 1829-40, 2013.
, “A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.”, J Infect Dis, vol. 203, no. 10, pp. 1396-404, 2011.
,